BIOTRONIK announced that it is releasing a new line of ProMRI implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds). The devices and matching leads are compatible, under certain conditions, for use under MRI, with the single-chamber ICDs rated safe for use even within 3 Tesla MRIs. All of the new devices are safe for use during full-body scans under 1.5 Tesla.
The new Sentus QP for the CRT-Ds is the world’s first quadripolar left-ventricular lead approved for safety under MRI and offers multiple electrical stimulation options when positioned within the coronary sinus.
The ICDs feature MorphMatch technology that minimizes unnecessary shocks and includes optimized anti-tachycardia pacing (ATP) to help tune the pacing of the device to each patient.
“When deciding on the right device for my heart failure patients, I want to make sure they will benefit as much as possible from cardiac resynchronization therapy,” said Dr. Klaus-Jürgen Gutleben, physician of internal medicine and cardiology at the Heart and Diabetes Center North Rhine-Westphalia, Germany, in a statement. “Clinical evidence demonstrates that patients have reduced mortality when they receive fewer inappropriate shocks. We also know it can greatly improve their mental well-being and satisfaction with the therapy. Detection criteria and morphology analysis help ensure my patients only receive the therapy they need.”